The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

OBJECTIVE: Ivabradine, a specific heart rate lowering therapy, has been shown in a randomised placebo-controlled study, Systolic HF Treatment with the I(f) Inhibitor Ivabradine Trial (SHI(f)T), to significantly reduce the composite end point of cardiovascular death and hospitalisation for worsening...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, A, Paracha, N, Davies, A, Branscombe, N, Cowie, M R, Sculpher, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Heart Failure
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078716/
https://www.ncbi.nlm.nih.gov/pubmed/24634022
http://dx.doi.org/10.1136/heartjnl-2013-304598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078716/
https://www.ncbi.nlm.nih.gov/pubmed/24634022
http://dx.doi.org/10.1136/heartjnl-2013-304598

Ejemplares similares